Toll-like receptor ligands
AssigneeInimmune Corporation
InventorsHelene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
Life of this patent
Estimating the term…
Abstract
Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
Claims17
1-44. (canceled)
A method of eliciting or enhancing, or modifying an immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I-a), or a pharmaceutically acceptable salt thereof,
- wherein,
- R2a, R2b, and R2c are each independently —CH(R10)(R11);
- R3a is —OP(O)(OH)2, —OSO3H, or —OCH2P(O)(OH)2;
- R3b is hydrogen or COOH, or an ester thereof;
- R10, at each occurrence, is independently C8-14alkyl;
- R11, at each occurrence, is independently —O—C(═O)C1-15alkyl, —O—C(═O)C1-15alkylene-Z2, —O—C2-16alkylene-Z2, or —O—C2-16alkyl;
- and
- Z2, at each occurrence, is independently phenyl or a 5- to 6-membered heteroaryl, wherein Z2 is optionally substituted with 1-5 substituents independently selected from C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, cyano, and halogen.
50-52. (canceled)
A method of treating, preventing, or reducing the susceptibility to an allergy, an autoimmune condition, an infectious disease, cancer, ischemia reperfusion, sepsis, or ocular diseases such as macular degeneration, ocular hypertension, and ocular infection, in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I-a), or a pharmaceutically acceptable salt thereof,
- wherein,
- R2a, R2b, and R2c are each independently —CH(R10)(R11);
- R3a is —OP(O)(OH)2, —OSO3H, or —OCH2P(O)(OH)2;
- R3b is hydrogen or COOH, or an ester thereof;
- R10, at each occurrence, is independently C8-14alkyl;
- R11, at each occurrence, is independently —O—C(═O)C1-15alkyl, —O—C(═O)C1-15alkylene-Z2, —O—C2-16alkylene-Z2, or —O—C2-16alkyl;
- and
- Z2, at each occurrence, is independently phenyl or a 5- to 6-membered heteroaryl, wherein Z2 is optionally substituted with 1-5 substituents independently selected from C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, cyano, and halogen.
54-55. (canceled)
(canceled)
A method of treating or preventing or reducing the severity of epileptic seizures comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I-a) or a pharmaceutically acceptable salt thereof,
- wherein,
- R2a, R2b, and R2c are each independently —CH(R10)(R11);
- R3a is —OP(O)(OH)2, —OSO3H, or —OCH2P(O)(OH)2;
- R3b is hydrogen or COOH, or an ester thereof;
- R10, at each occurrence, is independently C8-14alkyl;
- R11, at each occurrence, is independently —O—C(═O)C1-15alkyl, —O—C(═O)C1-15alkylene-Z2, —O—C2-16alkylene-Z2, or —O—C2-16alkyl;
- and
- Z2, at each occurrence, is independently phenyl or a 5- to 6-membered heteroaryl, wherein Z2 is optionally substituted with 1-5 substituents independently selected from C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, cyano, and halogen.
63-64. (canceled)
Dependencies are inferred from the claim text.